Patents Assigned to BLUEPRINT MEDICINES
-
Patent number: 11970498Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.Type: GrantFiled: February 8, 2023Date of Patent: April 30, 2024Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
-
Patent number: 11932648Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.Type: GrantFiled: June 27, 2022Date of Patent: March 19, 2024Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
-
Patent number: 11872192Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.Type: GrantFiled: July 16, 2021Date of Patent: January 16, 2024Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Erica Evans Raab, Beni B. Wolf
-
Publication number: 20220213553Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.Type: ApplicationFiled: January 21, 2022Publication date: July 7, 2022Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Nicolas STRANSKY, Joseph L. Kim
-
Publication number: 20220205045Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.Type: ApplicationFiled: September 30, 2021Publication date: June 30, 2022Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Nicolas STRANSKY, Joseph L. Kim
-
Patent number: 11279688Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: GrantFiled: January 29, 2020Date of Patent: March 22, 2022Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
-
Patent number: 11273160Abstract: Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.Type: GrantFiled: December 18, 2020Date of Patent: March 15, 2022Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Erica Evans Raab, Beni B. Wolf
-
Patent number: 10875930Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.Type: GrantFiled: July 30, 2014Date of Patent: December 29, 2020Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
-
Patent number: 10875837Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: GrantFiled: February 19, 2019Date of Patent: December 29, 2020Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
-
Patent number: 10774070Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.Type: GrantFiled: December 20, 2018Date of Patent: September 15, 2020Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
-
Publication number: 20200181715Abstract: The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PRKC fusions, such as conditions mediated by aberrant PRKC expression or activity, or overexpression of PRKC.Type: ApplicationFiled: July 16, 2019Publication date: June 11, 2020Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Nicolas Stransky, Joseph L. Kim
-
Publication number: 20200172981Abstract: The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with RAF1 fusions, such as conditions mediated by aberrant RAF1 expression or activity, or overexpression of RAF1.Type: ApplicationFiled: July 16, 2019Publication date: June 4, 2020Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Nicolas Stransky, Joseph L. Kim
-
Publication number: 20200109127Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: February 19, 2019Publication date: April 9, 2020Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
-
Patent number: 10584114Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: GrantFiled: July 20, 2018Date of Patent: March 10, 2020Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
-
Publication number: 20200031830Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: March 5, 2019Publication date: January 30, 2020Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Kevin J. Wilson, Josh Waetzig
-
Publication number: 20190359682Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.Type: ApplicationFiled: December 21, 2018Publication date: November 28, 2019Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Neil BIFULCO, JR., Natasja BROOIJMANS, Brian L. HODOUS, Joseph L. KIM, Chandrasekhar V. MIDUTURU
-
Publication number: 20190359591Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.Type: ApplicationFiled: December 20, 2018Publication date: November 28, 2019Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Natasja BROOIJMANS, Lucian V. DIPIETRO, Paul E. FLEMING, Joseph L. KIM, Steven Mark WENGLOWSKY, Yulian ZHANG
-
Patent number: 10370379Abstract: This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I:Type: GrantFiled: November 18, 2016Date of Patent: August 6, 2019Assignee: BLUEPRINT MEDICINES CORPORATIONInventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Jr., Joseph L. Kim
-
Publication number: 20190192522Abstract: Described herein are selective inhibitors of FGFR4, pharmaceutical compositions including such compounds, and combinations with other therapeutic agents, such as CDK inhibitors (e.g., CDK4/6 inhibitors), and methods of using such combinations.Type: ApplicationFiled: September 8, 2017Publication date: June 27, 2019Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Margit HAGEL, Klaus HOEFLICH, Christoph LENGAUER, Nicolas STRANSKY, Christopher WINTER, Lan XU
-
Publication number: 20190185942Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.Type: ApplicationFiled: February 27, 2019Publication date: June 20, 2019Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
